Nonsmall Cell Lung Cancer
Conditions
Brief summary
A Prospective Multi-center Study to Investigate the EGFR-TKI Resistance Profile in Chinese Patients with Advanced EGFRm+ NSCLC
Detailed description
Patients with EGFR mutation and presented secondary resistance to prior first-generation EGFR-TKI should have received biopsy of at least on progressed lesions and are able to provide tissues for pathological examination and NGS testing.All enrolled patients will be followed up to clinical outcome (treatments, tumor response, survival, etc).
Interventions
None listed
Sponsors
AstraZeneca
Jianxing He
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Provision of informed consent prior to any study specific procedures. * Male or female patients aged 18 years and older. * Histological confirmation of stage IIIB/IV NSCLC. * Documented EGFR mutation positive . * WHO Performance Status 0, 1 or 2
Exclusion criteria
* Any other significant clinical disorder or laboratory finding that made it undesirable for the patient to participate in the study. * Previous (within 6 months) or current treatment with AZD9291.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The biomarker profile of EGFR-TKI resistance | Baseline |
Secondary
| Measure | Time frame |
|---|---|
| The concordance, sensitivity and specificity in paired blood and tissue samples | Baseline |
Contacts
Primary ContactJian Xing HE, MD
Outcome results
None listed